Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1983 Mar;36(3):316–323. doi: 10.1136/jcp.36.3.316

Disordered function of mononuclear phagocytes in malignant disease.

R J Sokol, G Hudson
PMCID: PMC498204  PMID: 6338057

Full text

PDF
316

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander P. Macrophages and tumours. Schweiz Med Wochenschr. 1976 Oct 2;106(40):1345–1350. [PubMed] [Google Scholar]
  2. Bice D. E., Gruwell D., Salvaggio J. Inhibition of macrophage migration by plasma factor(s) from patients with neoplasms and normal individuals. J Reticuloendothel Soc. 1976 May;19(5):281–289. [PubMed] [Google Scholar]
  3. Birbeck M. S., Carter R. L. Observations on the ultrastructure of two hamster lymphomas with particular reference to infiltrating macrophages. Int J Cancer. 1972 Mar 15;9(2):249–257. doi: 10.1002/ijc.2910090202. [DOI] [PubMed] [Google Scholar]
  4. Boetcher D. A., Leonard E. J. Abnormal monocyte chemotactic response in cancer patients. J Natl Cancer Inst. 1974 Apr;52(4):1091–1099. doi: 10.1093/jnci/52.4.1091. [DOI] [PubMed] [Google Scholar]
  5. Brosman S., Hausman M. S. Defective monocyte chemotactic response in genitourinary carcinoma. Urology. 1974 Aug;4(2):129–134. doi: 10.1016/0090-4295(74)90322-7. [DOI] [PubMed] [Google Scholar]
  6. Cantarow W. D., Cheung H. T., Sundharadas G. Modulation of spreading, adhesion and migration of peritoneal macrophages by a low molecular weight factor extracted from mouse tumors. J Reticuloendothel Soc. 1978 Dec;24(6):657–666. [PubMed] [Google Scholar]
  7. Cline M. J. Defective mononuclear phagocyte function in patients with myelomonocytic leukemia and in some patients with lymphoma. J Clin Invest. 1973 Sep;52(9):2185–2190. doi: 10.1172/JCI107403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cooper E. H., Turner R., Steele L., Goligher J. C. Blood muramidase activity in colorectal cancer. Br Med J. 1974 Sep 14;3(5932):662–664. doi: 10.1136/bmj.3.5932.662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cruchaud A., Girard J. P., Hitoglou S. The functions of human monocytes in normal subjects and in disorders associated with immune deficiency. Int Arch Allergy Appl Immunol. 1977;54(6):529–537. doi: 10.1159/000231873. [DOI] [PubMed] [Google Scholar]
  10. Currie G. A., Alexander P. Spontaneous shedding of TSTA by viable sarcoma cells: its possible role in facilitating metastatic spread. Br J Cancer. 1974 Jan;29(1):72–75. doi: 10.1038/bjc.1974.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Currie G. A., Eccles S. A. Serum lysozyme as a marker of host resistance. I. Production by macrophages resident in rat sarcomata. Br J Cancer. 1976 Jan;33(1):51–59. doi: 10.1038/bjc.1976.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Currie G. A., Hedley D. W. Monocytes and macrophages in malignant melanoma. I. Peripheral blood macrophage precursors. Br J Cancer. 1977 Jul;36(1):1–6. doi: 10.1038/bjc.1977.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Currie G. A. Serum lysozyme as a marker of host resistance. II. Patients with malignant melanoma, hypernephroma or breast carcinoma. Br J Cancer. 1976 Jun;33(6):593–599. doi: 10.1038/bjc.1976.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. DIZON Q. S., SOUTHAM C. M. ABNORMAL CELLULAR RESPONSE TO SKIN ABRASION IN CANCER PATIENTS. Cancer. 1963 Oct;16:1288–1292. doi: 10.1002/1097-0142(196310)16:10<1288::aid-cncr2820161009>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  15. Dammacco F., Miglietta A., Ventura M. T., Bonomo L. Defective monocyte chemotactic responsiveness in patients with multiple myeloma and benign monoclonal gammapathy. Clin Exp Immunol. 1982 Feb;47(2):481–486. [PMC free article] [PubMed] [Google Scholar]
  16. Dent R. G., Cole P. In vitro monocyte maturation as a prediction of survival in squamous cell carcinoma of the lung. Thorax. 1981 Jun;36(6):446–451. doi: 10.1136/thx.36.6.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Dent R. G., Cole P. In vitro monocyte maturation in squamous carcinoma of the lung. Br J Cancer. 1981 Apr;43(4):486–495. doi: 10.1038/bjc.1981.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Eccles S. A., Alexander P. Macrophage content of tumours in relation to metastatic spread and host immune reaction. Nature. 1974 Aug 23;250(5468):667–669. doi: 10.1038/250667a0. [DOI] [PubMed] [Google Scholar]
  19. Estevez M. E., Sen L., Bachmann A. E., Pavlovsky A. Defective function of peripheral blood monocytes in patients with Hodgkin's and non-Hodgkin's lymphomas. Cancer. 1980 Jul 15;46(2):299–302. doi: 10.1002/1097-0142(19800715)46:2<299::aid-cncr2820460214>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  20. Fidler I. J. Activation in vitro of mouse macrophages by syngeneic, allogeneic, or xenogeneic lymphocyte supernatants. J Natl Cancer Inst. 1975 Nov;55(5):1159–1163. doi: 10.1093/jnci/55.5.1159. [DOI] [PubMed] [Google Scholar]
  21. Fortuny I. E., Deinard A., Theologides A. The Rebuck skin window as a guide in cancer chemotherapy. Cancer Treat Rep. 1976 Jul;60(7):903–906. [PubMed] [Google Scholar]
  22. Gauci C. L., Alexander P. The macrophage content of some human tumours. Cancer Lett. 1975 Sep;1(1):29–32. doi: 10.1016/s0304-3835(75)94826-0. [DOI] [PubMed] [Google Scholar]
  23. Ghosh M. L., Hudson G., Blackburn E. K. Skin window macrophages in malignant lymphomas. Br J Haematol. 1973 Sep;25(3):293–297. doi: 10.1111/j.1365-2141.1973.tb01740.x. [DOI] [PubMed] [Google Scholar]
  24. Goldsmith H. S., Levin A. G., Southam C. M. A study of cellular responses in cancer patients by qualitative and quantitative Rebuck tests. Surg Forum. 1965;16:102–104. [PubMed] [Google Scholar]
  25. Hansen N. E., Karle H. Elevated plasma lysozyme in Hodgkin's disease. An indicator of increased macrophage activity? Scand J Haematol. 1979 Feb;22(2):173–178. doi: 10.1111/j.1600-0609.1979.tb00418.x. [DOI] [PubMed] [Google Scholar]
  26. Haskill J. S., Proctor J. W., Yamamura Y. Host responses with solid tumors. I. Monocytic effector cells within rat sarcomas. J Natl Cancer Inst. 1975 Feb;54(2):387–393. [PubMed] [Google Scholar]
  27. Hausman M. S., Brosman S. A. Abnormal monocyte function in bladder cancer patients. J Urol. 1976 May;115(5):537–541. doi: 10.1016/s0022-5347(17)59271-x. [DOI] [PubMed] [Google Scholar]
  28. Hausman M. S., Brosman S., Snyderman R., Mickey M. R., Fahey J. Defective monocyte function in patients with genitourinary carcinoma. J Natl Cancer Inst. 1975 Nov;55(5):1047–1054. doi: 10.1093/jnci/55.5.1047. [DOI] [PubMed] [Google Scholar]
  29. Hedley D. W., Currie G. A. Monocytes and macrophages in malignant melanoma. III. Reduction of nitroblue tetrazolium by peripheral blood monocytes. Br J Cancer. 1978 May;37(5):747–752. doi: 10.1038/bjc.1978.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hedley D. W., Nyholm R. E., Currie G. A. Monocytes and macrophages in malignant melanoma IV. Effects of C. parvum on monocyte function. Br J Cancer. 1979 May;39(5):558–565. doi: 10.1038/bjc.1979.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Holm G., Björkholm M., Johansson B., Mellstedt H., Lindemalm C. Monocyte function in Hodgkin's disease. Clin Exp Immunol. 1982 Jan;47(1):162–168. [PMC free article] [PubMed] [Google Scholar]
  32. Israel L., Edelstein R., Mannoni P., Radot E., Greenspan E. M. Plasmapheresis in patients with disseminated cancer: clinical results and correlation with changes in serum protein. The concept of "nonspecific blocking factors". Cancer. 1977 Dec;40(6):3146–3154. doi: 10.1002/1097-0142(197712)40:6<3146::aid-cncr2820400659>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  33. Israël L., Edelstein R. In vivo and in vitro studies on nonspecific blocking factors of host origin in cancer patients. Role of plasma exchange as an immunotherapeutic modality. Isr J Med Sci. 1978 Jan;14(1):105–130. [PubMed] [Google Scholar]
  34. Israël L., Samak R., Eedelstein R. Defective monocyte killing in cancer patients. Lancet. 1980 Dec 13;2(8207):1311–1311. doi: 10.1016/s0140-6736(80)92385-5. [DOI] [PubMed] [Google Scholar]
  35. Kay A. B., McVie J. G. Monocyte chemotaxis in bronchial carcinoma and cigarette smokers. Br J Cancer. 1977 Oct;36(4):461–466. doi: 10.1038/bjc.1977.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Kerbel R. S., Davies A. J. The possible biological significance of Fc receptors on mammalian lymphocytes and tumor cells. Cell. 1974 Oct;3(2):105–112. doi: 10.1016/0092-8674(74)90113-5. [DOI] [PubMed] [Google Scholar]
  37. Kerbel R. S., Pross H. F., Elliott E. V. Origin and partial characterization of Fc receptor-bearing cells found within experimental carcinomas and sarcomas. Int J Cancer. 1975 Jun 15;15(6):918–932. doi: 10.1002/ijc.2910150607. [DOI] [PubMed] [Google Scholar]
  38. King G. W., Bain G., LoBuglio A. F. The effect of tuberculosis and neoplasia on human monocyte staphylocidal activity. Cell Immunol. 1975 Apr;16(2):389–395. doi: 10.1016/0008-8749(75)90127-6. [DOI] [PubMed] [Google Scholar]
  39. King G. W., Yanes B., Hurtubise P. E., Balcerzak S. P., LoBuglio A. F. Immune function of successfully treated lymphoma patients. J Clin Invest. 1976 Jun;57(6):1451–1460. doi: 10.1172/JCI108415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Kitahara M., Eyre H. J., Hill H. R. Monocyte functional and metabolic activity in malignant and inflammatory diseases. J Lab Clin Med. 1979 Mar;93(3):472–479. [PubMed] [Google Scholar]
  41. Kjeldsberg C. R., Pay G. D. A qualitative and quantitative study of monocytes in patients with malignant solid tumors. Cancer. 1978 Jun;41(6):2236–2241. doi: 10.1002/1097-0142(197806)41:6<2236::aid-cncr2820410624>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  42. Kleinerman E. S., Zwelling L. A., Howser D., Barlock A., Young R. C., Decker J. M., Bull J., Muchmore A. V. Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet. 1980 Nov 22;2(8204):1102–1105. doi: 10.1016/s0140-6736(80)92540-4. [DOI] [PubMed] [Google Scholar]
  43. Kohl S., Pickering L. K., Sullivan M. P., Walters D. L. Impaired monocyte-macrophage cytotoxicity in patients with Hodgkin's disease. Clin Immunol Immunopathol. 1980 Apr;15(4):577–585. doi: 10.1016/0090-1229(80)90001-x. [DOI] [PubMed] [Google Scholar]
  44. Krishnan E. C., Mebust W. K., Weigel J. W., Jewell W. R. Maturation of monocytes in patients with renal cell carcinoma. Invest Urol. 1981 Jul;19(1):4–7. [PubMed] [Google Scholar]
  45. Krishnan E. C., Menon C. D., Krishnan L., Jewell W. R. Deficiency in maturation process of macrophages in human cancer. J Natl Cancer Inst. 1980 Aug;65(2):273–276. [PubMed] [Google Scholar]
  46. Kuntz B. M., Kuntz R. M., Albert E. D. Phagocytosis of monocytes in cancer patients. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1978 Jan 26;91(1):11–17. doi: 10.1007/BF00305967. [DOI] [PubMed] [Google Scholar]
  47. Lauder I., Aherne W., Stewart J., Sainsbury R. Macrophage infiltration of breast tumours: a prospective study. J Clin Pathol. 1977 Jun;30(6):563–568. doi: 10.1136/jcp.30.6.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Leb L., Merritt J. A. Decreased monocyte function in patients with Hodgkin's disease. Cancer. 1978 May;41(5):1794–1803. doi: 10.1002/1097-0142(197805)41:5<1794::aid-cncr2820410522>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  49. Lukács K., Frendl G., Berényi E., Kávai M., Szabó G., Szegedi G. Monocyte chemotaxis and effect of levamisole in Hodgkin's disease. Acta Med Acad Sci Hung. 1980;37(2):145–150. [PubMed] [Google Scholar]
  50. MAHONEY M. J., LEIGHTON J. The inflammatory response to a foreign body within transplantable tumors. Cancer Res. 1962 Apr;22:334–338. [PubMed] [Google Scholar]
  51. Magarey C. J., Baum M. Reticulo-endothelial activity in humans with cancer. Br J Surg. 1970 Oct;57(10):748–752. doi: 10.1002/bjs.1800571013. [DOI] [PubMed] [Google Scholar]
  52. McVie J. G., Logan E. C., Kay A. B. Monocyte function in cancer patients. Eur J Cancer. 1977 Apr-May;13(4-5):351–353. doi: 10.1016/0014-2964(77)90080-9. [DOI] [PubMed] [Google Scholar]
  53. Norman S. J., Sorkin E. Cell-specific defect in monocyte function during tumor growth. J Natl Cancer Inst. 1976 Jul;57(1):135–140. doi: 10.1093/jnci/57.1.135. [DOI] [PubMed] [Google Scholar]
  54. Normann S. J., Schardt M., Sorkin E. Cancer progression and monocyte inflammatory dysfunction: relationship to tumour excision and metastasis. Int J Cancer. 1979 Jan 15;23(1):110–113. doi: 10.1002/ijc.2910230119. [DOI] [PubMed] [Google Scholar]
  55. Normann S. J., Sorkin E. Inhibition of macrophage chemotaxis by neoplastic and other rapidly proliferating cells in vitro. Cancer Res. 1977 Mar;37(3):705–711. [PubMed] [Google Scholar]
  56. Normann S. J. Tumor cell threshold required for suppression of macrophage inflammation. J Natl Cancer Inst. 1978 May;60(5):1091–1096. doi: 10.1093/jnci/60.5.1091. [DOI] [PubMed] [Google Scholar]
  57. Norris D. A., Perez R. E., Golitz L. E., Seitz L. E., Weston W. L. Defective monocyte chemotaxis in mycosis fungoides: lack of essential helper lymphocytes. Cancer. 1979 Jul;44(1):124–130. doi: 10.1002/1097-0142(197907)44:1<124::aid-cncr2820440122>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  58. North R. J., Kirstein D. P., Tuttle R. L. Subversion of host defense mechanisms by murine tumors. I. A circulating factor that suppresses macrophage-mediated resistance to infection. J Exp Med. 1976 Mar 1;143(3):559–573. doi: 10.1084/jem.143.3.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. North R. J., Kirstein D. P., Tuttle R. L. Subversion of host defense mechanisms by murine tumors. II. Counter-influence of concomitant antitumor immunity. J Exp Med. 1976 Mar 1;143(3):574–584. doi: 10.1084/jem.143.3.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Nyholm R. E., Currie G. A. Monocytes and macrophages in malignant melanoma. II. Lysis of antibody-coated human erythrocytes as an assay of monocyte function. Br J Cancer. 1978 Mar;37(3):337–344. doi: 10.1038/bjc.1978.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Otu A. A., Russell R. J., Wilkinson P. C., White R. G. Alterations of mononuclear phagocyte function induced by Lewis lung carcinoma in C57BL mice. Br J Cancer. 1977 Sep;36(3):330–340. doi: 10.1038/bjc.1977.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Parakkal P., Pinto J., Hanifin J. M. Surface morphology of human mononuclear phagocytes during maturation and phagocytosis. J Ultrastruct Res. 1974 Aug;48(2):216–226. doi: 10.1016/s0022-5320(74)80078-x. [DOI] [PubMed] [Google Scholar]
  63. Pasternack G. R., Snyderman R., Pike M. C., Johnson R. J., Shin H. S. Resistance of neoplasms to immunological destruction: role of a macrophage chemotaxis inhibitor. J Exp Med. 1978 Jul 1;148(1):93–102. doi: 10.1084/jem.148.1.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Pike M. C., Snyderman R. Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance. J Immunol. 1976 Oct;117(4):1243–1249. [PubMed] [Google Scholar]
  65. Pross H. F., Kerbel R. S. An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochthonous and early passaged chemically induced murine sarcomas. J Natl Cancer Inst. 1976 Nov;57(5):1157–1167. doi: 10.1093/jnci/57.5.1157. [DOI] [PubMed] [Google Scholar]
  66. REBUCK J. W., MONTO R. W., MONAGHAN E. A., RIDDLE J. M. Potentialities of the lymphocyte, with an additional reference to its dysfunction in Hodgkin's disease. Ann N Y Acad Sci. 1958 Sep 5;73(1):8–38. doi: 10.1111/j.1749-6632.1959.tb40790.x. [DOI] [PubMed] [Google Scholar]
  67. REBUCK J. W., MONTO R. W., MONAGHAN E. A., RIDDLE J. M. Potentialities of the lymphocyte, with an additional reference to its dysfunction in Hodgkin's disease. Ann N Y Acad Sci. 1958 Sep 5;73(1):8–38. doi: 10.1111/j.1749-6632.1959.tb40790.x. [DOI] [PubMed] [Google Scholar]
  68. Rabatić S., Jurin M., Dekaris D. In vitro suppression of macrophage spreading caused by supernatants of tumour, thymus, and lymph node cells. Folia Biol (Praha) 1977;23(5):317–326. [PubMed] [Google Scholar]
  69. RamaRao G. V., Tompkins W. A. Inhibition of macrophage phagocytosis by a human colon tumor cell factor. J Reticuloendothel Soc. 1978 May;23(5):373–387. [PubMed] [Google Scholar]
  70. Ree H. J., Crowley J. P., Leone L. A. Macrophage-histiocyte lysozyme activity in relation to the clinical presentation of Hodgkin's disease. An immunohistochemical study. Cancer. 1981 Apr 15;47(8):1988–1993. doi: 10.1002/1097-0142(19810415)47:8<1988::aid-cncr2820470815>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  71. Ree H. J., Song J. Y., Leone L. A., Crowley J. P., Fanger H. Occurrence and patterns of muramidase containing cells in Hodgkin's disease, non-Hodgkin's lymphomas, and reactive hyperplasia. Hum Pathol. 1981 Jan;12(1):49–59. doi: 10.1016/s0046-8177(81)80241-9. [DOI] [PubMed] [Google Scholar]
  72. Rhodes J. Altered expression of human monocyte Fc receptors in malignant disease. Nature. 1977 Jan 20;265(5591):253–255. doi: 10.1038/265253a0. [DOI] [PubMed] [Google Scholar]
  73. Rhodes J., Bishop M., Benfield J. Tumor surveillance: how tumors may resist macrophage-mediated host defense. Science. 1979 Jan 12;203(4376):179–182. doi: 10.1126/science.758686. [DOI] [PubMed] [Google Scholar]
  74. Rhodes J., Plowman P., Bishop M., Lipscomb D. Human macrophage function in cancer: systemic and local changes detected by an assay for Fc receptor expression. J Natl Cancer Inst. 1981 Mar;66(3):423–429. [PubMed] [Google Scholar]
  75. Rubin R. H., Cosimi A. B., Goetzl E. J. Defective human mononuclear leukocyte chemotaxis as an index of host resistance to malignant melanoma. Clin Immunol Immunopathol. 1976 Nov;6(3):376–388. doi: 10.1016/0090-1229(76)90091-x. [DOI] [PubMed] [Google Scholar]
  76. Ruco L. P., Procopio A., Uccini S., Baroni C. D. Increased monocyte phagocytosis in cancer patients. Eur J Cancer. 1980 Oct;16(10):1315–1320. doi: 10.1016/0014-2964(80)90288-1. [DOI] [PubMed] [Google Scholar]
  77. Russell S. W., McIntosh A. T. Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas. Nature. 1977 Jul 7;268(5615):69–71. doi: 10.1038/268069a0. [DOI] [PubMed] [Google Scholar]
  78. Saito H., Tomioka H. Suppressive factor against macrophage phagocytosis produced by cultured sarcoma-180 cells. Gan. 1979 Oct;70(5):671–675. [PubMed] [Google Scholar]
  79. Salky N. K., Di Luzio N. R., Levin A. G., Goldsmith H. S. Phagocytic activity of the reticuloendothelial system in neoplastic disease. J Lab Clin Med. 1967 Sep;70(3):393–403. [PubMed] [Google Scholar]
  80. Samak R., Edelstein R., Bogucki D., Samak M., Israël L. Testing the monocyte-macrophage system in human cancer. Biomedicine. 1980 Dec;32(4):165–169. [PubMed] [Google Scholar]
  81. Scheinberg M. A., Masuda A., Maluf J. A., Mendes N. F. Monocyte function in patients with solid neoplasms during immunotherapy with Corynebacterium parvum. Cancer. 1978 May;41(5):1761–1764. doi: 10.1002/1097-0142(197805)41:5<1761::aid-cncr2820410517>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  82. Seitz L. E., Golitz L. E., Weston W. L., Aeling J. E., Dustin R. D. Defective monocyte chemotaxis in mycosis fungoides. Arch Dermatol. 1977 Aug;113(8):1055–1057. [PubMed] [Google Scholar]
  83. Sheagren J. N., Block J. B., Wolff S. M. Reticuloendothelial system phagocytic function in patients with Hodgkin's disease. J Clin Invest. 1967 May;46(5):855–862. doi: 10.1172/JCI105585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Snyderman R., Meadows L., Holder W., Wells S., Jr Abnormal monocyte chemotaxis in patients with breast cancer: evidence for a tumor-mediated effect. J Natl Cancer Inst. 1978 Apr;60(4):737–740. doi: 10.1093/jnci/60.4.737. [DOI] [PubMed] [Google Scholar]
  85. Snyderman R., Seigler H. F., Meadows L. Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal. J Natl Cancer Inst. 1977 Jan;58(1):37–41. doi: 10.1093/jnci/58.1.37. [DOI] [PubMed] [Google Scholar]
  86. Sokol R. J., Durrant T. E., Hudson G. Scanning electron microscopy of skin window cells of normal subjects. J Anat. 1978 May;126(Pt 1):157–167. [PMC free article] [PubMed] [Google Scholar]
  87. Sokol R. J., Durrant T. E., Hudson G. Skin window cellularity and macrophage changes in Hodgkin's and non-Hodgkin's lymphomas. Acta Haematol. 1980;64(4):209–215. doi: 10.1159/000207253. [DOI] [PubMed] [Google Scholar]
  88. Sokol R. J., Durrant T. E., Lambourne C. A., Hudson G. Scanning electron microscopy of exudative macrophages in malignant lymphoma. Scand J Haematol. 1979 Feb;22(2):129–140. doi: 10.1111/j.1600-0609.1979.tb00413.x. [DOI] [PubMed] [Google Scholar]
  89. Spitalny G. L., North R. J. Subversion of host defense mechanisms by malignant tumors: an established tumor as a privileged site for bacterial growth. J Exp Med. 1977 May 1;145(5):1264–1277. doi: 10.1084/jem.145.5.1264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Steigbigel R. T., Lambert L. H., Jr, Remington J. S. Polymorphonuclear leukocyte, monocyte, and macrophage bactericidal function in patients with Hodgkin's disease. J Lab Clin Med. 1976 Jul;88(1):54–62. [PubMed] [Google Scholar]
  91. Taylor S. A., Currie G. A. Monocyte maturation and prognosis in primary breast cancer. Br Med J. 1979 Apr 21;1(6170):1050–1051. doi: 10.1136/bmj.1.6170.1050-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Trepel F., Begemann H. On the origin of the skin window macrophages. Acta Haematol. 1966;36(5):386–398. doi: 10.1159/000209419. [DOI] [PubMed] [Google Scholar]
  93. Underwood J. C. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer. 1974 Dec;30(6):538–548. doi: 10.1038/bjc.1974.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Urbanitz D., Fechner I., Gross R. Reduced monocyte phagocytosis in patients with advanced Hodgkin's disease and lymphosarcoma. Klin Wochenschr. 1975 May 1;53(9):437–440. doi: 10.1007/BF01493369. [DOI] [PubMed] [Google Scholar]
  95. VOLKMAN A., GOWANS J. L. THE PRODUCTION OF MACROPHAGES IN THE RAT. Br J Exp Pathol. 1965 Feb;46:50–61. [PMC free article] [PubMed] [Google Scholar]
  96. Van Loveren H., Den Otter W. Macrophages in solid tumors. I. Immunologically specific effector cells. J Natl Cancer Inst. 1974 Oct;53(4):1057–1060. doi: 10.1093/jnci/53.4.1057. [DOI] [PubMed] [Google Scholar]
  97. Ward P. A., Berenberg J. L. Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med. 1974 Jan 10;290(2):76–80. doi: 10.1056/NEJM197401102900203. [DOI] [PubMed] [Google Scholar]
  98. Wood G. W., Gillespie G. Y. Studies on the role of macrophages in regulation of growth and metastasis of murine chemically induced fibrosarcomas. Int J Cancer. 1975 Dec 15;16(6):1022–1029. doi: 10.1002/ijc.2910160616. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES